u/Far-East-locker

ServiceNow is down 15% after earnings, and everyone else in the sector is down 1–2%.

It seems like this will be the trend for this quarter: if one company falls, the whole sector gets punished.

With so many earnings lined up over the next two months, it could be a bloodbath.

Not saying you should sell, but if you want to buy the dip, maybe at least wait till this cycle end

Late April

• Apr 23: PD (PagerDuty), SAP (Enterprise/ERP)
• Apr 29: MSFT (Microsoft), CFLT (Confluent)
• Apr 30: TEAM (Atlassian), TWLO (Twilio)

Early May

• May 4: PLTR (Palantir)
• May 5: SHOP (Shopify), PCOR (Procore), KVYO (Klaviyo), FRSH (Freshworks)
• May 6: PAYC (Paycom), APP (AppLovin - Confirmed)
• May 7: DDOG (Datadog), NET (Cloudflare), HUBS (HubSpot), DBX (Dropbox), APPN (Appian), PCTY (Paylocity), U (Unity), TTD (The Trade Desk - Confirmed), TOST (Toast - Est)

Mid-Late May

• May 11: MNDY (monday.com)
• May 13: DT (Dynatrace - Est)
• May 14: FIG (Figma)
• May 19: PANW (Palo Alto Networks)
• May 20: SNOW (Snowflake), ZM (Zoom)
• May 21: WDAY (Workday), INTU (Intuit)
• May 26: OKTA (Okta), BOX (Box - Est)
• May 27: CRM (Salesforce), S (SentinelOne - Est)
• May 28: ESTC (Elastic), ZS (Zscaler)

June

• Jun 2: CRWD (CrowdStrike), ASAN (Asana - Est)
• Jun 3: PATH (UiPath - Est)
• Jun 4: DOCU (DocuSign - Est), MDB (MongoDB - Est)
• Jun 5: SMAR (Smartsheet - Est)
• Jun 8: GTLB (GitLab - Est)
• Jun 11: ADBE (Adobe)
• Jun 16: ORCL (Oracle - Est)

---

Note: Dates marked (Est) are based on historical trends.

Get out of SaaS now if you can.

Everyone is going to have a similar earnings report: a double beat, but with massive CapEx and the Middle East situation, guidance will be soft. Things won’t turn around until 2027 at the earliest.

Not only will the company gap down, but it will take another 1–2% hit every time another SaaS company reports.

These 'death by a thousand cuts' will be the main force dragging the whole industry’s stock price down.

In the last earnings report, ServiceNow beat on both top and bottom lines by a small margin, yet the stock dipped 11% and eventually dropped over 22% within four days.

It’s likely we’ll see another double beat tonight, but we might also see a repeat of last quarter's sell-off. The story is much the same, but the pressure on AI is even higher now with so many new tools hitting the market.

If ServiceNow falls, it won't be alone; it’ll likely trigger another wave of SaaS pullbacks.

In the last earnings report, ServiceNow beat on both top and bottom lines by a small margin, yet the stock dipped 11% and eventually dropped over 22% within four days.

It’s likely we’ll see another double beat tonight, but we might also see a repeat of last quarter's sell-off. The story is much the same, but the pressure on AI is even higher now with so many new tools hitting the market.

If ServiceNow falls, it won't be alone; it’ll likely trigger another wave of SaaS pullbacks.

Just curious.

I am not talking about asking ChatGPT "what is a good stock to pick," but actually utilizing AI to change your own or your company's way of doing business.

The drop is due to the news that Amazon is selling GLP-1 drugs. Basically, any telehealth company that sells GLP-1 is down.

However, strangely, NVO and LLY are down as well.

Back to the topic: if HIMS is not affected by the news, that means the market believes HIMS doesn’t need to rely on diet-drug revenue. We are totally priced in, even if HIMS is selling fewer and fewer diet pills.

Which is great, because I thought the next earnings report would see a pullback because of dropping diet-pill revenue. But the market no longer thinks that’s an issue and is instead focusing on the future of the other product lines, overseas markets, and peptides.

Instead of just yelling peptides i spent sometime to dig deeper to see what is the likely situation if peptides get put back into Category 1.

Right now the FDA just started the process of moving 12 popular peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, etc.) out of the restricted Category 2 list. They’ve got advisory meetings set for July 23-24 to decide on full Category 1 / 503A compounding approval.

And honestly? This puts telehealth companies like HIMS in an absolute sweet spot.

Even if they get the green light, it’s still risky enough that Big Pharma won’t touch it with a ten-foot pole. But telehealth + compounding pharmacies can sit way above the grey market — real doctor oversight, decent quality control, and they can charge premium prices for it.

HIMS already has their own peptide manufacturing facility and their CMO straight-up applauded the move. This feels like the exact bridge we’ve been waiting for: turning sketchy grey-market peptides into something your average person can actually get prescribed without feeling like they’re doing something shady.

Now some might argue users will just stick with the grey market stuff. And yeah, the grey market might even grow alongside it. But that’ll stay limited to the hardcore biohackers group. Everyone else finally gets a legit, convenient, and somewhat regulated option through telehealth companies.

Grey market never fully dies… but this could finally push peptides into the mainstream for normal people.

Besides GLP-1, their other revenue lines are growing.
https://www.reddit.com/r/HIMS/

Just looking at the hair loss product results, it is quite amazing.

I would say they are in a good position to legitimize some of the peptides. Right now, it is a grey market; you are buying from some unknown compounder in China. While it is cheap and looks like it works, I believe people will pay a premium to buy from an American brand.

Another main focus is their overseas adoption. They bought Eucalyptus, which is the market leader in Australia, the UK, and Germany. They are also expanding into Japan and Canada. If they can duplicate their model overseas, that will be a huge subscription gain.

The next earning call might pull them back a bit as their revenue will be hurt as they can't sell GLP-1 compound, however long term, if they execute as planned, i can see them at least going back to $70

We may see a short-term recovery from the SaaSpocalypse, I anticipate a steady long-term decline for software-only security firms. At least i don't want be get threaten every time Anthropic news coming up

For that I am pivoting my strategy toward hardware-anchored cybersecurity, like physical firewall (Fortinet), biometric security providers (Clear Secure Inc) and private cloud (NTNX)

let’s go

HIMS has been planning on this peptide play since last year. There was a 14% gain when RJK mentioned in on Joe Rogan podcast. Now that NYT reported it is going to happens, it gapped up 8% within one hours already